• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Lutropin-Choriogonadotropic Hormone Receptor (LHCGR) Human Recombinant Protein

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS960675

Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. More details

$315 / 0.02 mg (E-Coli) +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Lutropin-choriogonadotropic hormone receptor (LHCGR), Recombinant Protein
Full Product Name
Recombinant Human Lutropin-choriogonadotropic hormone receptor (LHCGR), partial
Product Gene Name
Product Synonym Names
Luteinizing hormone receptor; LHR; LSH-R
Sequence
EALCPEPCNC VPDGALRCPG PTAGLTRLSL AYLPVKVIPS QAFRGLNEVI KIEISQIDSL ERIEANAFDN LLNLSEILIQ NTKNLRYIEP GAFINLPRLK YLSICNTGIR KFPDVTKVFS SESNFILEIC DNLHITTIPG NAFQGMNNES VTLKLYGNGF EEVQSHAFNG TTLTSLELKE NVHLEKMHNG AFRGATGPKT LDISSTKLQA LPSYGLESIQ RLIATSSYSL KKLPSRETFV NLLEATLTYP SHCCAFRNLP TKEQNFSHSI SENFSKQCES TVRKVNNKTL YSSMLAESEL SGWDYEYGFC LPKTPRCAPE PDAFNPCEDI MGYDFLR
Host
E Coli or Yeast or Baculovirus or Mammalian Cell
Form/Format
Lyophilized or liquid (Format to be determined during the manufacturing process)
Purity/Purification
Greater or equal to 85% purity as determined by SDS-PAGE. (lot specific)
Preparation and Storage
Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.
Molecular Weight
39.6 kDa
Sequence Positions
27-363aa; Partial
Tag Information
This protein contains an N-terminal tag and may also contain a C-terminal tag. Tag types are determined by various factors including tag-protein stability, please inquire for tag information.
Sterility
Sterile filter available upon request.
Endotoxin
Low endotoxin available upon request.
OMIM
152790
3D Structure
ModBase 3D Structure for P22888
Production Note
Special Offer: The E Coli host-expressed protein is manufactured from a stock plasmid containing the protein gene. E Colihost-expressed protein is stocked in different unit sizes ranging from as small as 10 ug to as large as 1 mg. Bulk inventory is also available. The E Coli host-expressed protein has been ordered over and over again by researchers and has stood the test of time as both a robust protein and important target for the research community. It is part of our new program to make our most popular protein targets and corresponding hosts available in expanded unit sizes and with a quick processing time. Select E Coli host-expressed protein for the fastest delivery among all hosts. Please contact our technical support team or email to support@mybiosource.com for more details.

Product Categories/Family for LHCGR recombinant protein

ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.

Product References and Citations for LHCGR recombinant protein

Cloning and sequencing of human LH/hCG receptor cDNA.Minegish T., Nakamura K., Takakura Y., Miyamoto K., Hasegawa Y., Ibuki Y., Igarashi M.Biochem. Biophys. Res. Commun. 172:1049-1054(1990) Expression of human luteinizing hormone (LH) receptor interaction with LH and chorionic gonadotropin from human but not equine, rat, and ovine species.Jia X.-C., Oikawa M., Bo M., Tanaka T., Ny T., Boime I., Hsueh A.J.W.Mol. Endocrinol. 5:759-768(1991) Isolation of TSH and LH/CG receptor cDNAs from human thyroid regulation by tissue specific splicing.Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L., Cone R.D.Mol. Endocrinol. 4:1264-1276(1990) Structure of the human luteinizing hormone-choriogonadotropin receptor gene unusual promoter and 5' non-coding regions.Atger M., Misrahi M., Sar S., Leflem L., Dessen P., Milgrom E.Mol. Cell. Endocrinol. 111:113-123(1995) Generation and annotation of the DNA sequences of human chromosomes 2 and 4.Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., Wilson R.K.Nature 434:724-731(2005) Genomic distribution and gonadal mRNA expression of two human luteinizing hormone receptor exon 1 sequences in random populations.Tsai-Morris C.-H., Geng Y., Buczko E., Dehejia A., Dufau M.L.Hum. Hered. 49:48-51(1999) Evidence that palmitoylation of carboxyl terminus cysteine residues of the human luteinizing hormone receptor regulates postendocytic processing.Munshi U.M., Clouser C.L., Peegel H., Menon K.M.Mol. Endocrinol. 19:749-758(2005) Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions.Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H., Hendrickson W.A., el Tayar N.Structure 3:1341-1353(1995) Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys a novel constitutively activating mutation in the first transmembrane helix.Latronico A.C., Shinozaki H., Guerra G. Jr., Pereira M.A.A., Lemos Marini S.H.V., Baptista M.T.M., Arnhold I.J.P., Fanelli F., Mendonca B.B., Segaloff D.L.J. Clin. Endocrinol. Metab. 85:4799-4805(2000) Nodular Leydig cell hyperplasia in a boy with familial male-limited precocious puberty.Leschek E.W., Chan W.-Y., Diamond D.A., Kaefer M., Jones J., Barnes K.M., Cutler G.B. Jr.J. Pediatr. 138:949-951(2001) Mutant luteinizing hormone receptors in a compound heterozygous patient with complete Leydig cell hypoplasia abnormal processing causes signaling deficiency.Martens J.W.M., Lumbroso S., Verhoef-Post M., Georget V., Richter-Unruh A., Szarras-Czapnik M., Romer T.E., Brunner H.G., Themmen A.P.N., Sultan C.J. Clin. Endocrinol. Metab. 87:2506-2513(2002) Luteinizing hormone signaling and breast cancer polymorphisms and age of onset.Powell B.L., Piersma D., Kevenaar M.E., van Staveren I.L., Themmen A.P.N., Iacopetta B.J., Berns E.M.J.J.J. Clin. Endocrinol. Metab. 88:1653-1657(2003) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.Shenker A., Laue L., Kosugi S., Merendino J.J. Jr., Minegishi T., Cutler G.B. Jr.Nature 365:652-654(1993) Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty.Kremer H., Mariman E., Otten B.J., Moll G.W. Jr., Stoelinga G.B.A., Wit J.M., Jansen M., Drop S.L., Faas B., Ropers H.-H., Brunner H.G.Hum. Mol. Genet. 2:1779-1783(1993) Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty.Kosugi S., van Dop C., Geffner M.E., Rabl W., Carel J.-C., Chaussain J.-L., Mori T., Merendino J.J. Jr., Shenker A.Hum. Mol. Genet. 4:183-188(1995) A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty.Yano K., Saji M., Hidaka A., Moriya N., Okuno A., Kohn L.D., Cutler G.B. Jr.J. Clin. Endocrinol. Metab. 80:1162-1168(1995) A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty.Latronico A.C., Anasti J., Arnhold I.J., Mendonca B.B., Domenice S., Albano M.C., Zachman K., Wajchenberg B.L., Tsigos C.J. Clin. Endocrinol. Metab. 80:2490-2494(1995) Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene.Kremer H., Kraaij R., Toledo S.P.A., Post M., Fridman J.B., Hayashida C.Y., van Reen M., Milgrom E., Ropers H.-H., Mariman E., Themmen A.P.N., Brunner H.G.Nat. Genet. 9:160-164(1995) A missense (T577I) mutation in the luteinizing hormone receptor gene associated with familial male-limited precocious puberty.Cocco S., Meloni A., Marini M.G., Cao A., Moi P.3.3.CO;2-B>Hum. Mutat. 7:164-166(1996) A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty genotype does not always correlate with phenotype.Evans B.A.J., Bowen D.J., Smith P.J., Clayton P.E., Gregory J.W.J. Med. Genet. 33:143-147(1996) Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene.Latronico A.C., Anasti J., Arnhold I.J.P., Rapaport R., Mendonca B.B., Bloise W., Castro M., Tsigos C., Chrousos G.P.N. Engl. J. Med. 334:507-512(1996) Comparison of immunocytochemical and molecular features with the phenotype in a case of incomplete male pseudohermaphroditism associated with a mutation of the luteinizing hormone receptor.Misrahi M., Meduri G., Pissard S., Bouvattier C., Beau I., Loosfelt H., Jolivet A., Rappaport R., Milgrom E., Bougneres P.J. Clin. Endocrinol. Metab. 82:2159-2165(1997) Polymorphisms in the coding exons of the human luteinizing hormone receptor gene.Wu S.-M., Jose M., Hallermeier K., Rennert O.M., Chan W.-Y.3.0.CO;2-D>Hum. Mutat. 11:333-334(1998) A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty.Gromoll J., Partsch C.-J., Simoni M., Nordhoff V., Sippell W.G., Nieschlag E., Saxena B.B.J. Clin. Endocrinol. Metab. 83:476-480(1998) A novel mutation of the human luteinizing hormone receptor in 46XY and 46XX sisters.Stavrou S.S., Zhu Y.S., Cai L.Q., Katz M.D., Herrera C., Defillo-Ricart M., Imperato-Mcginley J.J. Clin. Endocrinol. Metab. 83:2091-2098(1998) A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty.Latronico A.C., Abell A.N., Arnhold I.J., Liu X., Lins T.S., Brito V.N., Billerbeck A.E., Segaloff D.L., Mendonca B.B.J. Clin. Endocrinol. Metab. 83:2435-2440(1998) Evidences for an allelic variant of the human LC/CG receptor rather than a gene duplication functional comparison of wild-type and variant receptors.Rodien P., Cetani F., Costagliola S., Tonacchera M., Duprez L., Minegishi T., Govaerts C., Vassart G.J. Clin. Endocrinol. Metab. 83:4431-4434(1998) A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor.Latronico A.C., Chai Y., Arnhold I.J.P., Liu X., Mendonca B.B., Segaloff D.L.Mol. Endocrinol. 12:442-450(1998) A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia correlation between receptor activity and phenotype.Martens J.W., Verhoef-Post M., Abelin N., Ezabella M., Toledo S.P., Brunner H.G., Themmen A.P.Mol. Endocrinol. 12:775-784(1998) Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor.Liu G., Duranteau L., Carel J.-C., Monroe J., Doyle D.A., Shenker A.N. Engl. J. Med. 341:1731-1736(1999) A novel missense homozygous inactivating mutation in the fourth transmembrane helix of the luteinizing hormone receptor in Leydig cell hypoplasia.Leung M.Y.-K., Al-Muslim O., Wu S.-M., Aziz A., Inam S., Awadh M., Rennert O.M., Chan W.-Y.Am. J. Med. Genet. A 130:146-153(2004) Leydig cell hypoplasia absent luteinizing hormone receptor cell surface expression caused by a novel homozygous mutation in the extracellular domain.Richter-Unruh A., Verhoef-Post M., Malak S., Homoki J., Hauffa B.P., Themmen A.P.N.J. Clin. Endocrinol. Metab. 89:5161-5167(2004) The consensus coding sequences of human breast and colorectal cancers.Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.Science 314:268-274(2006) A splice site mutation combined with a novel missense mutation of LHCGR cause male pseudohermaphroditism.Qiao J., Han B., Liu B.-L., Chen X., Ru Y., Cheng K.-X., Chen F.-G., Zhao S.-X., Liang J., Lu Y.-L., Tang J.-F., Wu Y.-X., Wu W.-L., Chen J.-L., Chen M.-D., Song H.-D.Hum. Mutat. 30:E855-E865(2009) +Additional computationally mapped references.<p>Provides general information on the entry.

Other Notes

Small volumes of LHCGR recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for LHCGR purchase

MBS960675 is a recombinant protein targeting LHCGR. Also known as Recombinant Human Lutropin-choriogonadotropic hormone receptor (LHCGR), partial. Host: E Coli or Yeast or Baculovirus or Mammalian Cell.

Additional Details

NCBI/Uniprot data below describe general gene information for LHCGR. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
lutropin-choriogonadotropic hormone receptor
NCBI Official Synonym Full Names
luteinizing hormone/choriogonadotropin receptor
NCBI Official Symbol
LHCGR
NCBI Official Synonym Symbols
HHG; LHR; LCGR; LGR2; ULG5; LHRHR; LSH-R; LH/CGR; LH/CG-R
UniProt Protein Name
Lutropin-choriogonadotropic hormone receptor
UniProt Synonym Protein Names
Luteinizing hormone receptor; LHR; LSH-R
UniProt Gene Name
LHCGR
UniProt Synonym Gene Names
LCGR; LGR2; LHRHR; LH/CG-R; LHR; LSH-R
UniProt Entry Name
LSHR_HUMAN
NCBI Protein Information
lutropin-choriogonadotropic hormone receptor

NCBI Summary for LHCGR

This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]
Show more

UniProt Comments for LHCGR

LHR: Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Defects in LHCGR are a cause of familial male precocious puberty (FMPP); also known as testotoxicosis. In FMPP the receptor is constitutively activated. Defects in LHCGR are the cause of luteinizing hormone resistance (LHR); also known as Leydig cell hypoplasia in males. LHR is an autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias. Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: GPCR, family 1; Membrane protein, multi-pass; Receptor, GPCR; Membrane protein, integral

Chromosomal Location of Human Ortholog: 2p21

Cellular Component: endosome; integral to plasma membrane; plasma membrane

Molecular Function: lutropin-choriogonadotropic hormone receptor activity; peptide receptor activity, G-protein coupled

Biological Process: adenylate cyclase activation; cognition; G-protein coupled receptor protein signaling pathway; G-protein signaling, adenylate cyclase activating pathway; G-protein signaling, coupled to cyclic nucleotide second messenger; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); hormone-mediated signaling; luteinizing hormone signaling pathway; male genitalia development; male gonad development; ovulation cycle process; positive regulation of inositol trisphosphate biosynthetic process

Disease: Leydig Cell Hypoplasia, Type I; Precocious Puberty, Male-limited
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000